News Valerio Therapeutics London S.E.

Stocks

0NWK

FR0010095596

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:37:56 2024-10-14 EDT			5-day change	1st Jan Change
0.0860 ^EUR	-.--%		-80.93%	-36.53%

07-16	Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies	MT
07-16	Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates	MT

All News

Mentions Relevance

07-16	Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update	BU
07-16	Valerio Therapeutics : Announces Development Collaboration with Abivax and Provides Pipeline Update	PU
07-01	Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines	BU
07-01	Valerio Therapeutics : announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines	PU
06-30	Valerio Therapeutics Société anonyme signed a letter of intent to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million.	CI
06-17	Valerio Therapeutics Appoints New Chief Executive Officer
06-17	Valerio Therapeutics Names New CEO	MT
06-16	Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting	BU
06-16	Valerio Therapeutics Société Anonyme Announces Board and Executive Changes	CI
06-16	Valerio Therapeutics Société Anonyme Announces CEO Changes	CI
06-16	Valerio Therapeutics : Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting	PU
05-19	Valerio Therapeutics Signs Binding Term-sheet for V-Body Platform Collaboration	MT
05-18	Valerio Therapeutics enters into collaboration & exclusive license with seed-stage biotech co	RE
05-18	Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company	BU
05-18	Valerio Therapeutics Enters Binding Term-Sheet for Collaboration and Exclusive License with Stealth-Mode Biotech Company	CI
05-18	Valerio Therapeutics : announces binding term-sheet for collaboration and exclusive license with seed-stage biotech company	PU
05-04	Valerio Therapeutics : Inside Information / Other news releases	PU
05-04	Valerio Therapeutics Announces Launch of Invimmune and Provides Update on in Vivo Cell Therapy Approaches	CI
05-04	Valerio Therapeutics Launches New Company for In Vivo Cell Therapies	MT
05-04	Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches	BU
04-29	Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report	PU
04-29	Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model	BU
04-28	Valerio Therapeutics : publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating model	PU
04-28	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-05	Valerio Therapeutics, Biggest Decline on the SRD at Midday Monday, January 5, 2026